These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3274481)

  • 1. Prognostic significance of hepatitis B surface antigenemia in cadaveric renal transplant patients.
    Rivolta E; De Vecchi A; Tarantino A; Castelnovo C; Berardinelli L; Ponticelli C
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2153-4. PubMed ID: 3274481
    [No Abstract]   [Full Text] [Related]  

  • 2. Cadaveric renal transplantation after pulsatile perfusion, histocompatibility matching, and conversion to cyclosporine therapy.
    Milgrom M; Kyriakides GK; Esquenazi V; Olson L; Miller J
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1873. PubMed ID: 3274444
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal transplantation in hepatitis B surface antigen-positive patients.
    White AG; Kumar MS; Strannegard O; Abouna GM
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2150-2. PubMed ID: 3274480
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis B and renal transplantation.
    Scott D; Mijch A; Lucas CR; Marshall V; Thomson N; Atkins R
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2159-60. PubMed ID: 3274482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage.
    Fabrizio F; Bunnapradist S; Martin P
    J Nephrol; 2002; 15(6):605-13. PubMed ID: 12495272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of hepatitis B infection on the outcome of renal allotransplantation.
    Flagg GL; Silberman H; Takamoto SK; Berne TV
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2155-8. PubMed ID: 3547916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cyclosporine on the clinical course of HBsAg-positive renal transplant patients.
    Stempel C; Lake J; Ferrell L; Tomlanovich S; Amend W; Salvatierra O; Vincenti F
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1251-2. PubMed ID: 1989202
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic Epstein-Barr virus reactivation after renal transplantation: immunosuppression with cyclosporine versus azathioprine.
    Hillebrand G; Castro LA; Schleibner S; Land W; Gurland HJ
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2179-80. PubMed ID: 2856280
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparable success rates are now possible for higher- and lower-risk cadaveric kidney transplant recipients.
    Feduska NJ; Melzer JS; Salvatierra O
    Clin Transpl; 1987; ():209-16. PubMed ID: 3154404
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of HBsAg-positivity of kidney donors on long-term patient and graft outcome.
    Berber I; Aydin C; Yigit B; Turkmen F; Titiz IM; Altaca G
    Transplant Proc; 2005 Dec; 37(10):4173-5. PubMed ID: 16387070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion of cyclosporine to azathioprine in renal transplant patients.
    Shen SY; Zemel SM; Weir MR; Dagher FJ; Bentley FR
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2032-6. PubMed ID: 3547906
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of DR and DR6 matching on cadaver kidney transplant survival.
    Reyman TA; Toledo-Pereyra LH
    Transplant Proc; 1987 Feb; 19(1 Pt 1):702-4. PubMed ID: 3274848
    [No Abstract]   [Full Text] [Related]  

  • 13. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract]   [Full Text] [Related]  

  • 14. Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial.
    Friend PJ; Calne RY; Hale G; Waldmann H; Evans DB; Rolles K; Thiru S; Gore S
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1898-900. PubMed ID: 3079058
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatitis B surface antigenemia in renal transplant recipients. Increased mortality risk.
    Hillis WD; Hillis A; Walker WG
    JAMA; 1979 Jul; 242(4):329-32. PubMed ID: 376886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of hepatitis B and C virus on kidney transplantation outcome.
    Mathurin P; Mouquet C; Poynard T; Sylla C; Benalia H; Fretz C; Thibault V; Cadranel JF; Bernard B; Opolon P; Coriat P; Bitker MO
    Hepatology; 1999 Jan; 29(1):257-63. PubMed ID: 9862875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney transplantations with HBsAg+ donors.
    Bedrossian J; Akposso K; Metivier F; Moal MC; Pruna A; Idatte JM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1481-2. PubMed ID: 8442160
    [No Abstract]   [Full Text] [Related]  

  • 18. Current advantage of FK 506 in cadaveric kidney transplantation.
    Ciancio G; Rosen A; Loreto-Grand B; Burke G; Siquijor A; Luque C; Esquenazi V; Miller J
    Transplant Proc; 1996 Apr; 28(2):1000-1. PubMed ID: 8623207
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of blood transfusions and HLA on cyclosporine-treated renal transplant recipients.
    Kerman RH; Van Buren CT; Lewis RM; Kahan BD
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):264-9. PubMed ID: 3291254
    [No Abstract]   [Full Text] [Related]  

  • 20. Triple and quadruple therapy after renal transplantation in patients from developing countries.
    Slapak M; Shell T; Digard N; Gosling DC; Qerchi della Rovera G; Crockett RC; Ahmed K
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1922-5. PubMed ID: 3547896
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.